Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluimucil and rosuvastatin for systemic effects in COPD
2006-000978-68Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Aug 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of acetylcysteine and rosuvastatin in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Lung function (flow-volume before and after COMBIVENT). Started Aug 2006; status: active.
02
Drugs
acetylcysteinerosuvastatin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2006-000978-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000978-68.